Variable | Valuea |
---|---|
Vestibule doses (Gy) | |
Minimum | 2.6 (0.05–6.2) |
Mean | 6.7 (0.3–10.8) |
Maximum | 11 (2–17) |
Target volume doses (Gy) | |
Minimum | 11.3 (6.2–12) |
Mean | 12.7 (11.8–17.7) |
Maximum | 13 (12.1–23) |
Transient volume expansion | 18 (34) |
Post-SRS tumor necrosis | 31 (58) |
Patient-reported dizziness | |
Stable/improved | 40 (75.5) |
Worsened | 8 (15) |
No data available | 5 (9.5) |
Clinical examination | |
Spontaneous nystagmus | |
Stable/improved | 29 (55) |
Worsened | 9 (17.5) |
No data available | 15 (28.5) |
Romberg test | |
Stable/improved | 27 (51) |
Worsened | 2 (4) |
No data available | 24 (45) |
Unterberger test | |
Stable/improved | 19 (36) |
Worsened | 10 (19) |
No data available | 24 (45) |
Vestibular tests | |
Video-oculography | |
No spontaneous nystagmus | 22 (42) |
Spontaneous nystagmus | 3 (5) |
Pathologic smooth pursuit | 3 (5) |
No data available | 25 (48) |
Stable/improved | 24 (45) |
Worsened | 2 (4) |
Caloric ips. testing | |
Normal (0–25%) | 2 (4) |
Mild hypofunction (26–50%) | 9 (17.5) |
Moderate hypofunction (51–75%) | 3 (5) |
Severe hypofunction (76–100%) | 11 (21) |
Percentage caloric weakness (%) | 76 (2–100) |
No data available | 28 (52.5) |
Stable/improved | 12 (23) |
Worsened | 13 (24.5) |
cVEMP | |
Normal | 7 (13) |
Absent reflex | 14 (26) |
No data available | 32 (60.5) |
Stable/improved | 13 (24.5) |
Worsened | 2 (4) |